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Immunotherapy represents a promising area of therapy among neuro-
oncology patients. However, early phase studies reveal unique challenges as-
sociated with assessment of radiological changes reflecting delayed responses
or therapy-induced inflammation. Clinical benefit, including long-term sur-
vival and tumor regression, can still occur following initial apparent progres-
sion or appearance of new lesions. Refinement of response assessment criteria
for neuro-oncology patients undergoing immunotherapy is therefore warrant-
ed. A multinational and multidisciplinary panel of neuro-oncology immuno-
therapy experts describes immunotherapy response assessment for
neuro-oncology (iRANO) criteria that are based on guidance for determina-
tion of tumor progression outlined by the immune-related response criteria
(irRC) and the response assessment in neuro-oncology (RANO) working
group.Amongpatientswhodemonstrate imagingfindings meetingRANO cri-
teria for progressive disease (PD) within six months of initiating immunother-
apy including the development of new lesions, confirmation of radiographic
progression on follow-up imaging is recommended provided that the patient
is not significantly worse clinically. The proposed criteria also include guide-
lines for use of corticosteroids. The role of advanced imaging techniques and
measurement of clinical benefit endpoints including neurologic and immuno-
logic functions are reviewed. The iRANO guidelines put forth herein will
evolvesuccessively to improve their utilityas further experience fromimmuno-
therapy trials in neuro-oncology accumulate.
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